139 related articles for article (PubMed ID: 3222782)
1. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and anticoagulant effect of hirudin in man.
Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
5. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of hirudin.
Vogel G; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):113-8. PubMed ID: 2459004
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
Bichler J; Fichtl B; Siebeck M; Fritz H
Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
[TBL] [Abstract][Full Text] [Related]
8. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
9. The pharmacology of recombinant hirudin, a new anticoagulant.
Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
[TBL] [Abstract][Full Text] [Related]
10. Endotoxin-induced disseminated intravascular coagulation in rabbits: effect of recombinant hirudin on hemostatic parameters, fibrin deposits, and mortality.
Hermida J; Montes R; Páramo JA; Rocha E
J Lab Clin Med; 1998 Jan; 131(1):77-83. PubMed ID: 9452130
[TBL] [Abstract][Full Text] [Related]
11. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
13. The effect of a long-acting recombinant hirudin (PEG-hirudin) on experimental disseminated intravascular coagulation (DIC) in rabbits.
Zawilska K; Zozulinska M; Turowiecka Z; Blahut M; Drobnik L; Vinazzer H
Thromb Res; 1993 Feb; 69(3):315-20. PubMed ID: 8475480
[TBL] [Abstract][Full Text] [Related]
14. Influence of hirudin on the consumption of antithrombin III in experimental DIC.
Hauptmann J; Brüggener E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):83-7. PubMed ID: 2459037
[TBL] [Abstract][Full Text] [Related]
15. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy.
Saito M; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Matsuda T
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):60-4. PubMed ID: 7540878
[TBL] [Abstract][Full Text] [Related]
16. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
17. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC).
Ishikawa A; Hafter R; Seemüller U; Gokel JM; Graeff H
Thromb Res; 1980 Aug; 19(3):351-8. PubMed ID: 7434319
[No Abstract] [Full Text] [Related]
18. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
20. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin.
Dickneite G; Czech J; Keuper H
Circ Shock; 1994 Apr; 42(4):183-9. PubMed ID: 8055664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
